PMEF
TBPH icon

Point72 Middle East FZE’s Theravance Biopharma TBPH Stock Holding History

Point72 Middle East FZE’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,649
Closed -$40.9K – 2190
2022
Q4 		$40.9K Buy
+3,649
New +$38.4K ﹤0.01% 1499

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Point72 Middle East FZE's TBPH Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Theravance Biopharma (TBPH) in Q1 2023, closing a stake of 3,649 shares — an estimated $40.9K sold.

Point72 Middle East FZE first reported a position in TBPH in Q4 2022 and held it in 1 quarter. The position peaked at $40.9K in Q4 2022. 113 funds tracked by Wall St. Rank hold TBPH as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Theravance Biopharma position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 3,649 Theravance Biopharma shares in Q1 2023, an estimated $40.9K.
  • Point72 Middle East FZE first reported a position in Theravance Biopharma in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Theravance Biopharma position peaked at $40.9K in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.